Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Other Announcement

Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.

Sun Pharma Advanced Research Company Promoter Reclassification

Sun Pharma Advanced Research Company has submitted an application to stock exchanges to reclassify certain members from 'Promoter Group' to 'Public' category.

Sun Pharma Advanced Research Company Annual General Meeting

SPARC held its 21st Annual General Meeting on August 10, 2026, via video conferencing. The meeting covered routine business, including adoption of financial statements.

Sun Pharma Advanced Research Company Other Announcement

Sun Pharma Advanced Research Company Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms zero deviation in utilizing proceeds from its Rs. 599.98 Crore warrant issue.

Value

₹600.0 Cr

Sun Pharma Advanced Research Company Q1 FY27 Results: Net Loss of ₹20.8 Cr, Loss Narrows

Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹39.9 Cr (+315.6% YoY) and a net loss of ₹20.8 Cr for Q1 FY27.

Key figure

Net loss ₹20.8 Cr

Sun Pharma Advanced Research Company Board Meeting Date

Sun Pharma Advanced Research Company Limited scheduled a Board Meeting for August 10, 2026. The meeting will consider unaudited financial results for the period ended June 2026.

Sun Pharma Advanced Research Company Promoter Reclassification

Sun Pharma Advanced Research Company has received requests from certain Promoter Group members to reclassify their status to the 'Public' category.

Sun Pharma Advanced Research Company Other Announcement

Sun Pharma Advanced Research Company Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details equity holdings across promoter and public categories.

Sun Pharma Advanced Research Company Business Update

Sun Pharma Advanced Research Company submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report detailing ESG initiatives forms part of the Annual Report.

Sun Pharma Advanced Research Company Annual General Meeting

SPARC scheduled its 21st AGM for August 10, 2026, via video conference. Agenda includes adopting FY26 financials and appointing Anil Kumar Raghavan as MD and CEO.

Sun Pharma Advanced Research Company Annual Report

Sun Pharma Advanced Research Company submitted its FY 2025-26 Annual Report. The 21st AGM is scheduled for August 10, 2026, via video conferencing.

Sun Pharma Advanced Research Company Management Change

SPARC appointed Anil Raghavan as Managing Director and CEO effective August 11, 2026. Dr. Rajamannar Thennati will retire from the Board on August 10, 2026.

Sun Pharma Advanced Research Company Annual General Meeting

The 21st AGM of Sun Pharma Advanced Research Company will be held on 10 Aug 2026 via video conference. Electronic voting is open until 3 Aug 2026.

Sun Pharma Advanced Research Company Management Change

Sun Pharma Advanced Research Company announced senior management changes. Mr. Prasanna Deshmukh is appointed as Functional Head of HR & Administration.

Sun Pharma Advanced Research Company Adverse Business Impact

Sun Pharma Advanced Research Company terminated its license agreement with CMS Bridging DMCC. The company reports no material impact on its financial position or operations.

Sun Pharma Advanced Research Company Fund Raise of ₹150 Cr

SPARC received ₹149.99 Crore from Shanghvi Finance via a preferential allotment of 3,85,10,000 warrants. The capital infusion strengthens the company's financial position for future growth.

Value

₹150.0 Cr

Sun Pharma Advanced Research Company Business Update

SPARC's partner Ocuvex received a US FDA Complete Response Letter for the PDP-716 drug application. The FDA cited manufacturing inspection findings but raised no other issues.

Sun Pharma Advanced Research Company Fund Raise of ₹600 Cr

SPARC allotted 3.85 crore convertible warrants at ₹155.80 each to Shanghvi Finance on a preferential basis. The ₹599.99 Crore raise strengthens capital for future growth.

Value

₹600.0 Cr

Sun Pharma Advanced Research Company Q4 FY26 Results: Turns Profitable, Net Profit ₹1,761 Cr

Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹1,853 Cr (+6713.2% YoY) and net profit of ₹1,761 Cr for Q4 FY26.

Key figure

Net profit ₹1,761 Cr

Sun Pharma Advanced Research Company Financial Results

SPARC reported audited FY26 results, highlighted by a ₹1,840.02 Crore income from a voucher sale. The company remains focused on pharmaceutical research and development.

Value

₹1,840 Cr

Sun Pharma Advanced Research Company Board Meeting Date

Sun Pharma Advanced Research Company Limited scheduled a board meeting for May 18, 2026. Directors will review and approve audited financial results.

Sun Pharma Advanced Research Company Merger & Restructuring Worth ₹1,833 Cr

Sun Pharma Advanced Research Company Ltd (SPARC) has agreed to sell its FDA-granted Priority Review Voucher for US $195 million (₹1833.00 Crore). The transaction, subject to customary closing conditions and HSR antitrust clearance, will provide significant capital to accelerate SPARC's internal pipeline development and strengthen its innovation strategy.

Value

₹1,833 Cr

Sun Pharma Advanced Research Company Other Announcement

Sun Pharma Advanced Research Company (SPARC) submitted its quarterly compliance certificate for the period ended March 31, 2026. The certificate confirms that securities received for dematerialisation were processed and listed on stock exchanges within prescribed timelines. This is a routine regulatory filing with no material financial impact.

Sun Pharma Advanced Research Company Management Change

Sun Pharma Advanced Research Company Limited (SPARC) announced the resignation of Dr. Shravanti Bhowmik, Head of Operations Management and VP - Operations Management. Her resignation is effective from the close of business hours on March 31, 2026, as she transitions to a new opportunity within the group company.